Clinical observation of sunitinib treatment for refractory advanced breast cancer ulcer
OBJECTIVE: To observe the preliminary efficacies and adverse events of sunitinib in the treatment of metastatic breast cancer ulcer.
METHODS: From December 2008 to May 2010, patients with advanced breast cancer ulcer took a single sunitinib. The dosage was adjusted on the basis of adverse events. And clinical response was evaluated.
RESULTS: Nine patients with advanced breast cancer ulcer finished the treatment. The objective response and the clinical benefit time to progression of sunitinib were 3 and 7 patients with metastatic breast cancer ulcer, and the median time to progression (TTP) was 2.0 months. The most common adverse events included fatigue, hand-foot syndrome, neutropenia, thrombocytopenia and hypertension.
CONCLUSION: Single-agent sunitinib treatment of refractory advanced breast cancer ulcer has marked efficacies. However, neutropenia, thrombocytopenia and hypertension are the major dose-limited toxicities.
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2013 |
|---|---|
| Erschienen: |
2013 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:93 |
|---|---|
| Enthalten in: |
Zhonghua yi xue za zhi - 93(2013), 2 vom: 08. Jan., Seite 96-8 |
| Sprache: |
Chinesisch |
|---|
| Beteiligte Personen: |
Zhao, Xin [VerfasserIn] |
|---|
| Themen: |
Antineoplastic Agents |
|---|
| Anmerkungen: |
Date Completed 11.08.2014 Date Revised 02.01.2021 published: Print Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM227267621 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM227267621 | ||
| 003 | DE-627 | ||
| 005 | 20231224073339.0 | ||
| 007 | tu | ||
| 008 | 231224s2013 xx ||||| 00| ||chi c | ||
| 028 | 5 | 2 | |a pubmed24n0757.xml |
| 035 | |a (DE-627)NLM227267621 | ||
| 035 | |a (NLM)23648343 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a chi | ||
| 100 | 1 | |a Zhao, Xin |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Clinical observation of sunitinib treatment for refractory advanced breast cancer ulcer |
| 264 | 1 | |c 2013 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Date Completed 11.08.2014 | ||
| 500 | |a Date Revised 02.01.2021 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a OBJECTIVE: To observe the preliminary efficacies and adverse events of sunitinib in the treatment of metastatic breast cancer ulcer | ||
| 520 | |a METHODS: From December 2008 to May 2010, patients with advanced breast cancer ulcer took a single sunitinib. The dosage was adjusted on the basis of adverse events. And clinical response was evaluated | ||
| 520 | |a RESULTS: Nine patients with advanced breast cancer ulcer finished the treatment. The objective response and the clinical benefit time to progression of sunitinib were 3 and 7 patients with metastatic breast cancer ulcer, and the median time to progression (TTP) was 2.0 months. The most common adverse events included fatigue, hand-foot syndrome, neutropenia, thrombocytopenia and hypertension | ||
| 520 | |a CONCLUSION: Single-agent sunitinib treatment of refractory advanced breast cancer ulcer has marked efficacies. However, neutropenia, thrombocytopenia and hypertension are the major dose-limited toxicities | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Observational Study | |
| 650 | 7 | |a Antineoplastic Agents |2 NLM | |
| 650 | 7 | |a Indoles |2 NLM | |
| 650 | 7 | |a Pyrroles |2 NLM | |
| 650 | 7 | |a Sunitinib |2 NLM | |
| 650 | 7 | |a V99T50803M |2 NLM | |
| 700 | 1 | |a Meng, Xiang-ying |e verfasserin |4 aut | |
| 700 | 1 | |a Sun, Bing |e verfasserin |4 aut | |
| 700 | 1 | |a Ding, Li-juan |e verfasserin |4 aut | |
| 700 | 1 | |a Jiang, Ze-fei |e verfasserin |4 aut | |
| 700 | 1 | |a Song, San-tai |e verfasserin |4 aut | |
| 700 | 1 | |a Wu, Shi-kai |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Zhonghua yi xue za zhi |d 1994 |g 93(2013), 2 vom: 08. Jan., Seite 96-8 |w (DE-627)NLM000566861 |x 0376-2491 |7 nnns |
| 773 | 1 | 8 | |g volume:93 |g year:2013 |g number:2 |g day:08 |g month:01 |g pages:96-8 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 93 |j 2013 |e 2 |b 08 |c 01 |h 96-8 | ||